Ocugen, Inc. (OCGN)

$ 6.3218
0.0618 (+0.99%)
-
Symbol OCGN
Price $ 6.3218
Beta 2.594
Volume Avg. 65.48M
Market Cap 1.25B
Shares () -
52 Week Range 0.185-18.77
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -102.82% Strong Sell
ROA -46.34% Strong Sell
Operating Margin -
Debt / Equity 15.83% Neutral
P/E -
P/B 25.33 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. and Encourages Investors with Losses to Contact the Firm

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ocu...

Los Angeles, California--(Newsfile Corp. - June 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN...

Newsfile Corp
It's Time to Admit Defeat and Dump Ocugen Stock as a Covid Play

It's Time to Admit Defeat and Dump Ocugen Stock as a Covid Play

After the FDA rejected Covaxin, Ocugen has almost no chance of generating profits from the shot. OCGN stock is a great short. ...

InvestorPlace
Ocugen Inc. Set to Join Russell 3000® Index

Ocugen Inc. Set to Join Russell 3000® Index

MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COV... ...

GlobeNewsWire
OCGN Stock Price Increased 2.12%: Why It Happened

OCGN Stock Price Increased 2.12%: Why It Happened

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by 2.12% yesterday. This is why it happened. ...

Pulse2
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ocugen, Inc. - OCGN

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ocugen, Inc. - O...

NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN).  Such investors are advised to contact Robert S. ...

PRNewsWire
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation - OCGN

ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors with Losses in Excess o...

NEW YORK, June 15, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) resulting from allegations that Ocugen ... ...

PRNewsWire
OCGN Stock: Ocugen Fans Should Be Cheering This COVAXIN News

OCGN Stock: Ocugen Fans Should Be Cheering This COVAXIN News

OCGN stock saw a glimmer of hope today. Where the company took a hit last week in deserting EUA, it is gaining today with a new partnership. ...

InvestorPlace
Why Ocugen Stock Rallied Today

Why Ocugen Stock Rallied Today

The biotech is bolstering its production capabilities for an experimental coronavirus vaccine. ...

The Motley Fool
Options Traders Speculate on OCGN After Vaccine Update

Options Traders Speculate on OCGN After Vaccine Update

The shares of biopharmaceutical concern Ocugen Inc (NASDAQ:OCGN) are surging this afternoon, last seen up 7.2% to trade at $6.56. ...

Schaeffers Research
Ocugen Stock Jumps After Recruiting Jubilant HollisterStier As Manufacturing Partner For COVID-19 Vaccine Candidate

Ocugen Stock Jumps After Recruiting Jubilant HollisterStier As Manufacturing Partner For COVID-19 Va...

Ocugen Inc (NASDAQ: OCGN) has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVID-19 vaccine candidate, Covaxin for the U.S. and Canadian markets. "Securing US-based manufacturing capability is a critical st... ...

Benzinga

About


Dr. Shankar Musunuri
Healthcare
Biotechnology
Nasdaq Global Select

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 49 full-time employees. The firm offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The firm is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The firm is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).